{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T10:59:20Z","timestamp":1763809160852},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Fulminant hepatic failure is a serious disease with significant mortality and morbidity. Identifying the exact cause of hepatic failure and predicting prognosis is of paramount importance in managing such patients. Drug-induced liver injury is a common but challenging entity to treat. The use of newer drugs and medications with previously unknown hepatotoxicity add to the challenges faced by treating physicians. Quetiapine is an antipsychotic that has rarely been linked to acute liver injury. In the present work we describe a case of fulminant hepatic failure secondary to use of quetiapine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>A 59-year-old Caucasian woman with known Parkinson\u2019s disease was being treated with quetiapine for hallucinations. She was referred to our hospital with yellow discoloration of the sclera and later on developed clinical features suggestive of hepatic encephalopathy. A diagnosis of fulminant hepatic failure was made following her admission to the intensive care unit. Her condition improved after discontinuing the drug and providing the standard supportive treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our findings in the present report emphasize the importance of keeping an open mind in cases of fulminant hepatic failure. As drug-induced hepatotoxicity is the most common cause of fulminant hepatic failure in many parts of the world, consideration should be given to the medication(s) patients receive as the potential cause and a review of this list should be part of the clinical care given.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1752-1947-6-418","type":"journal-article","created":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T15:14:55Z","timestamp":1355325295000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Fulminant hepatic failure in association with quetiapine: a case report"],"prefix":"10.1186","volume":"6","author":[{"given":"Fawaz","family":"Al Mutairi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turki","family":"Al Ameel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,12]]},"reference":[{"key":"2378_CR1","first-page":"282","volume-title":"Prognosis in Liver Disease","author":"C Trey","year":"1970","unstructured":"Trey C, Davidson LS: The management of fulminant hepatic failure. Prognosis in Liver Disease. Edited by: Popper H, Shaffiner F. 1970, Grune and Stratton, New York, NY, 282-"},{"key":"2378_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1055\/s-2008-1040593","volume":"6","author":"J Bernauau","year":"1986","unstructured":"Bernauau J, Reuff B, Benhamou JP: Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis. 1986, 6: 97-10.1055\/s-2008-1040593.","journal-title":"Semin Liver Dis"},{"key":"2378_CR3","first-page":"240","volume":"21","author":"JH Hoofnagle","year":"1995","unstructured":"Hoofnagle JH, Carithers RL, Shapiro C, Ascher N: Fulminant hepatic failure: summary of a workshop. Hepatology. 1995, 21: 240-252.","journal-title":"Hepatology"},{"key":"2378_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/lt.500050102","volume":"5","author":"FV Schiodt","year":"1999","unstructured":"Schiodt FV, Atillasoy E, Shakil AO, Schiff ER, Caldwell C, Kowdley KV, Stribling R, Crippin JS, Flamm S, Somberg KA, Rosen H, McCashland TM, Hay JE, Lee WM: Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg. 1999, 5: 29-34. 10.1002\/lt.500050102.","journal-title":"Liver Transpl Surg"},{"key":"2378_CR5","first-page":"1046","volume-title":"Drug Information Handbook","author":"C Lacy","year":"2001","unstructured":"Lacy C, Armstrong L, Goldman M, Lance L: Quetiapine. Drug Information Handbook. 2001, Lexi-comp Inc, Hudson, OH, 1046-1047. 9","edition":"9"},{"key":"2378_CR6","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1016\/S0149-2918(00)89080-3","volume":"23","author":"J Mullen","year":"2001","unstructured":"Mullen J, Jibson MD, Sweitzer D: A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther. 2001, 23: 1839-1854. 10.1016\/S0149-2918(00)89080-3.","journal-title":"Clin Ther"},{"key":"2378_CR7","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/00019442-200311000-00018","volume":"11","author":"A Iraqi","year":"2003","unstructured":"Iraqi A: A case report of pancytopenia with quetiapine use. Am J Geriatr Psychiatry. 2003, 11: 694-","journal-title":"Am J Geriatr Psychiatry"},{"key":"2378_CR8","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1345\/aph.1G067","volume":"39","author":"M Huynh","year":"2005","unstructured":"Huynh M, Chee K, Lau DH: Thrombotic thrombocytopenic purpura associated with quetiapine. Ann Pharmacother. 2005, 39: 1346-1348. 10.1345\/aph.1G067.","journal-title":"Ann Pharmacother"},{"key":"2378_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1176\/jnp.14.1.87","volume":"14","author":"JA Bourgeois","year":"2002","unstructured":"Bourgeois JA, Babine S, Meyerovich M, Doyle J: A case of neuroleptic malignant syndrome with quetiapine. J Neuropsychiatry Clin Neurosci. 2002, 14: 87-10.1176\/appi.neuropsych.14.1.87.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2378_CR10","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1176\/appi.ajp.159.9.1608","volume":"159","author":"M Alexiadis","year":"2002","unstructured":"Alexiadis M, Whitehorn D, Woodley H, Kopala L: Prolactin elevation with quetiapine. Am J Psychiatry. 2002, 159: 1608-1609. 10.1176\/appi.ajp.159.9.1608.","journal-title":"Am J Psychiatry"},{"key":"2378_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/00004850-200503000-00011","volume":"20","author":"L Velayudhan","year":"2005","unstructured":"Velayudhan L, Kirchner V: Quetiapine-induced myoclonus. Int Clin Psychopharmacol. 2005, 20: 119-120. 10.1097\/00004850-200503000-00011.","journal-title":"Int Clin Psychopharmacol"},{"key":"2378_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0033-3182(00)71175-3","volume":"41","author":"P Gajwani","year":"2000","unstructured":"Gajwani P, Pozuelo L, Tesar GE: QT interval prolongation associated with quetiapine (Seroquel) overdose. Psychosomatics. 2000, 41: 63-65. 10.1016\/S0033-3182(00)71175-3.","journal-title":"Psychosomatics"},{"key":"2378_CR13","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1097\/00042737-200412000-00029","volume":"16","author":"I El Hajj","year":"2004","unstructured":"El Hajj I, Sharara AI, Rockey DC: Subfulminant liver failure associated with quetiapine. Eur J Gastroenterol Hepatol. 2004, 16: 1415-1418. 10.1097\/00042737-200412000-00029.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2378_CR14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1176\/appi.ajp.2010.10091292","volume":"168","author":"MI Naharci","year":"2011","unstructured":"Naharci MI, Karadurmus N, Demir O, Bozoglu E, Ak M, Doruk H: Fatal hepatotoxicity in an elderly patient receiving low-dose quetiapine. Am J Psychiatry. 2011, 168: 212-213. 10.1176\/appi.ajp.2010.10091292.","journal-title":"Am J Psychiatry"},{"key":"2378_CR15","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1097\/MEG.0b013e3282f8e3a0","volume":"20","author":"A Shpaner","year":"2008","unstructured":"Shpaner A, Li W, Ankoma-Sey V, Botero RC: Drug-induced liver injury: hepatotoxicity of quetiapine revisited. Eur J Gastroenterol Hepatol. 2008, 20: 1106-1109. 10.1097\/MEG.0b013e3282f8e3a0.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2378_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.4088\/JCP.v61n0403","volume":"61","author":"BJ McConville","year":"2000","unstructured":"McConville BJ, Arvanitis LA, Thyrum PT, Yeh C, Wilkinson LA, Chaney RO, Foster KD, Sorter MT, Friedman LM, Brown KL, Heubi JE: Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry. 2000, 61: 252-260. 10.4088\/JCP.v61n0403.","journal-title":"J Clin Psychiatry"},{"key":"2378_CR17","first-page":"1","volume-title":"Quetiapine (seroquel). Product monograph","author":"Zeneca Pharma Ltd","year":"1998","unstructured":"Zeneca Pharma Ltd: Quetiapine (seroquel). Product monograph. 1998, Zeneca, London, UK, 1-25."},{"key":"2378_CR18","doi-asserted-by":"publisher","first-page":"947","DOI":"10.7326\/0003-4819-137-12-200212170-00007","volume":"137","author":"G Ostapowicz","year":"2002","unstructured":"Ostapowicz G, Fontana RJ, Schi\u00f8dt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM, US Acute Liver Failure Study Group: Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002, 137: 947-954.","journal-title":"Ann Intern Med"},{"key":"2378_CR19","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/0168-8278(90)90124-A","volume":"11","author":"C B\u00e9nichou","year":"1990","unstructured":"B\u00e9nichou C: Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990, 11: 272-276.","journal-title":"J Hepatol"},{"key":"2378_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/s-2002-30101","volume":"22","author":"D Larrey","year":"2002","unstructured":"Larrey D: Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002, 22: 145-155. 10.1055\/s-2002-30101.","journal-title":"Semin Liver Dis"},{"key":"2378_CR21","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","volume":"46","author":"G Danan","year":"1993","unstructured":"Danan G, Benichou C: Causality assessment of adverse reactions to drugs\u2013I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993, 46: 1323-1330. 10.1016\/0895-4356(93)90101-6.","journal-title":"J Clin Epidemiol"},{"key":"2378_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/0016-5085(89)90081-4","volume":"97","author":"JG O\u2019Grady","year":"1989","unstructured":"O\u2019Grady JG, Alexander GJ, Hayllar KM, Williams R: Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989, 97: 439-445.","journal-title":"Gastroenterology"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-6-418.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1752-1947-6-418\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-6-418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-6-418.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T21:05:05Z","timestamp":1630530305000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/1752-1947-6-418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["2378"],"URL":"https:\/\/doi.org\/10.1186\/1752-1947-6-418","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"21 March 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"418"}}